American Society of HematologyCytomegalovirus-Specific T-Cell Reconstitution Following Letermovir Prophylaxis After Hematopoietic Cell Transplantation

Letermovir is a recently approved antiviral shown to decrease clinically significant cytomegalovirus (CMV) infection after hematopoietic cell transplantation (HCT) in a phase 3, randomized, placebo-controlled trial. Appearing in Blood, the authors make two key points: 1) Letermovir prophylaxis may be associated with decreased polyfunctional CMV-specific T-cell immunity after HCT, and 2) COMPASS is an analytical […]

American Medical AssociationEffect of Postreinduction Therapy Consolidation w. Blinatumomab vs. Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults w. First Relapse of B-Cell ALL

In this Original Investigation from JAMA, the authors discuss the results of a randomized clinical trial that included 208 patients with high- and intermediate-risk first relapse of B-cell acute lymphoblastic leukemia (ALL). Did postreinduction treatment with blinatumomab compared with chemotherapy, followed by hematopoietic stem cell transplant, result in a statistically significant difference in disease-free survival?

Millennium Medical PublishingTransfusion Replacement Strategies in Jehovah’s Witnesses and Others Who Decline Blood Products

This article reviews a variety of options that are available to aid in caring for patients who refuse blood transfusions, ranging from tranexamic acid to erythropoiesis-stimulating agents. With the use of these treatments, patients who decline blood transfusion can be safely managed in situations ranging from elective surgery to stem cell transplant to pregnancy.